CombiMatrix

Type: Company
Name: CombiMatrix
First reported Aug 28 2014 - Updated Aug 29 2014 - 4 reports

CombiMatrix CFO Scott R. Burell Purchases 1,000 Shares (CBMX)

CombiMatrix (NASDAQ:CBMX) CFO Scott R. Burell acquired 1,000 shares of CombiMatrix stock in a transaction that occurred on Wednesday, August 27th. The stock was purchased at an average cost of $2.04 per share, with a total value of $2,040.00. Following ... [Published American Banking News - Aug 29 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

Dark Clouds Gather Around CombiMatrix

By The Linch Scale :CombiMatrix (NASDAQ: CBMX ) is a small biotech nano- cap specializing in cytogenomic testing for prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. As a full-scale cytogenetic and cytogenomic laboratory, ... [Published BioPortfolio - Aug 28 2014]
First reported Aug 18 2014 - Updated Aug 18 2014 - 1 reports

CombiMatrix wins conditional approval from NYDOH for miscarriage analysis test

CombiMatrix Corporation, a molecular diagnostics company, has announced that its SNP-based chromosomal microarray analysis, or CMA, test for miscarriage analysis, the CombiSNP Array for Pregnancy Loss, or products of conception, has received conditional ... [Published Individual.com - Aug 18 2014]
First reported Aug 18 2014 - Updated Aug 18 2014 - 1 reports

Insider Selling: CombiMatrix Director Sells $27,358 in Stock (CBMX)

CombiMatrix (NASDAQ:CBMX) Director R Judd Jessup unloaded 13,679 shares of the company’s stock on the open market in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $2.00, for a total transaction of $27,358.00. Following ... [Published American Banking News - Forex - Aug 18 2014]
First reported Aug 15 2014 - Updated Aug 15 2014 - 1 reports

Insider Selling: CombiMatrix Director Sells 13,679 Shares of Stock (CBMX)

CombiMatrix (NASDAQ:CBMX) Director R Judd Jessup sold 13,679 shares of CombiMatrix stock in a transaction that occurred on Wednesday, August 13th. The stock was sold at an average price of $2.00, for a total value of $27,358.00. Following the sale, the ... [Published American Banking News - Aug 15 2014]
First reported Aug 11 2014 - Updated Aug 11 2014 - 2 reports

CombiMatrix Turns In Another Record Quarter, Stock Remains Undervalued

By Brian Marckx :CombiMatrix Corporation (NASDAQ: CBMX ) announced financial results for the second quarter ending June 30th, on August 7th. Aside from a large litigation expense, results were very much in line with our numbers. Importantly, almost all ... [Published BioPortfolio - Aug 11 2014]
First reported Aug 08 2014 - Updated Aug 08 2014 - 1 reports

CombiMatrix Rating Reiterated by Zacks (CBMX)

CombiMatrix (NASDAQ:CBMX)Zacks’ analyst wrote, "Molecular diagnostics company CBMX has offered a variety of genetic tests for various indications but just recently shifted the majority of its focus for growth on chromosomal microarray analysis (CMA) in ... [Published American Banking News - Aug 08 2014]
First reported Aug 06 2014 - Updated Aug 07 2014 - 1 reports

CombiMatrix misses by $0.04, revenue in-line

CombiMatrix (NASDAQ: CBMX ): Q2 EPS of -$0.23 misses by $0.04 . Revenue of $1.9M (+26.7% Y/Y) in-line. Shares +1.9% . Press Release Post your comment! ... [Published Seeking Alpha - Aug 06 2014]
Entities: CombiMatrix
First reported Aug 07 2014 - Updated Aug 07 2014 - 1 reports

Hot Stock: CombiMatrix, Shares Drop 6.5% (CBMX)

CombiMatrix (NASDAQ:CBMX) is one of today's worst performing low-priced stocks, down 6.5% to $2.01 on 1.0x average daily volume. CombiMatrix has traded 257,000 shares thus far today, vs. average volume of 248,000 shares per day. The stock has underperformed ... [Published Individual.com - Aug 07 2014]
First reported Aug 07 2014 - Updated Aug 07 2014 - 1 reports

CombiMatrix's (CBMX) CEO Mark McDonough on Q2 2014 Results - Earnings Call Transcript

OperatorGreetings, and welcome to the CombiMatrix Corporation Second Quarter 2014 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. (Operator ... [Published Seeking Alpha - Aug 07 2014]
First reported Jul 30 2014 - Updated Jul 31 2014 - 4 reports

CombiMatrix's SNP-Based Miscarriage Analysis Test Granted Conditional Approval From New York State Department of Health

(GLOBE NEWSWIRE) -- (Nasdaq:CBMX), a molecular diagnostics company performing DNA-based testing services for developmental disorders and cancer diagnostics, today announced that its SNP-based chromosomal microarray analysis (CMA) test for miscarriage ... [Published EMoneyDaily - Jul 31 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

CombiMatrix Pediatric Development Disorders Test Granted Conditional Approval

The New York State Department of Health has granted conditional approval for use of the CombiSNP array for pediatric analysis on patient samples.A chromosomal microarray analysis (CMA) test intended to identify development disorders in pediatric patients, ... [Published Clinical Lab Products - Jul 25 2014]

Quotes

So, what's at stake here? Apparently, a lot. CBMX has claimed Dr. Strathmann is not pursuing this lawsuit solely for the public benefit because "he seeks to personally recover 'at least 40% but not greater than 50% of the proceeds of this action' which could result in an award to Strathmann of between $30 million and $37.5 million."
...the flexibility to either use fresh tissue or stored FFPE tissue when fresh tissue is not available," said Mark McDonough, CEO of CombiMatrix. "In addition, this conditional license is the second this month, following conditional approval to market our CombiSNP CMA test for pediatric analysis, and the third since last year that we have received from the New York Department of Health. This approval enables CombiMatrix to market both of our CMA miscarriage analysis tests in New York state. We view these conditional approvals as validation of our regulatory and clinical capabilities to bring new test solutions to our customers."
Zacks’ analyst wrote, "Molecular diagnostics company CBMX has offered a variety of genetic tests for various indications but just recently shifted the majority of its focus for growth on chromosomal microarray analysis (CMA) in the prenatal setting. A relatively novel genetic testing method, CMA has gained more attention due to two recent NEJM-published studies and a recommendation from an influential trade association supporting its use in prenatal analysis. CBMX is positioning itself to exploit an industry shift away from the current standard testing method towards CMA by expanding distribution, entering into key partnerships and leveraging competitive advantages. Early indications are that this plan is already bearing fruit. "
...efficacy study should it be required to move forward to a NDA submission for Egalet-001," said Bob Radie, president and chief executive officer. "Based on our PK results plus our robust Category 1 abuse-deterrent data and the ongoing Category 2/3 study, we are committed to advancing Egalet-001 to fill an unmet need in the marketplace where there are no abuse-deterrent morphine products currently available for individuals living with chronic pain."

More Content

All (35) | News (26) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (9)
sort by: Date | Relevance
CombiMatrix CFO Scott R. Burell Purchases 1,000... [Published American Banking News - Aug 29 2014]
Insider Buying: Mark D. Mcdonough Acquires 12,0... [Published American Banking News - Forex - Aug 28 2014]
CombiMatrix CEO Acquires $24,240 in Stock (CBMX) [Published American Banking News - Aug 28 2014]
Dark Clouds Gather Around CombiMatrix [Published BioPortfolio - Aug 28 2014]
Dark Clouds Gather Around CombiMatrix [Published Seeking Alpha - Aug 28 2014]
CombiMatrix wins conditional approval from NYDO... [Published Individual.com - Aug 18 2014]
Insider Selling: CombiMatrix Director Sells $27... [Published American Banking News - Forex - Aug 18 2014]
Insider Selling: CombiMatrix Director Sells 13,... [Published American Banking News - Aug 15 2014]
CombiMatrix Turns In Another Record Quarter, St... [Published BioPortfolio - Aug 11 2014]
CombiMatrix Turns In Another Record Quarter, St... [Published Seeking Alpha - Aug 11 2014]
CombiMatrix Rating Reiterated by Zacks (CBMX) [Published American Banking News - Aug 08 2014]
Hot Stock: CombiMatrix, Shares Drop 6.5% (CBMX) [Published Individual.com - Aug 07 2014]
CombiMatrix's (CBMX) CEO Mark McDonough on Q2 2... [Published Seeking Alpha - Aug 07 2014]
Egalet Announces Topline Results From Egalet-00... [Published BioMedReports - Aug 07 2014]
CombiMatrix misses by $0.04, revenue in-line [Published Seeking Alpha - Aug 06 2014]
CombiMatrix Reports Second Quarter 2014 Financi... [Published GlobeNewswire: Acquisitions News - Aug 06 2014]
CombiMatrix's SNP-Based Miscarriage Analysis Te... [Published EMoneyDaily - Jul 31 2014]
CombiMatrix's SNP-Based Miscarriage Analysis Te... [Published RCL Advisors - Jul 31 2014]
CombiMatrix Corporation to Release Second Quart... [Published Wall Street Select - Jul 30 2014]
CombiMatrix : to Release Second Quarter Financi... [Published 4 Traders - Jul 30 2014]
CombiMatrix Pediatric Development Disorders Tes... [Published Clinical Lab Products - Jul 25 2014]
CombiMatrix Signs Contract With Stratose Networ... [Published GlobeNewswire: Advertising News - Jul 22 2014]
CombiMatrix's Pediatric Development Disorders A... [Published GlobeNewswire: Advertising News - Jul 15 2014]
Global Nanomedicine Market: Industry Analysis, ... [Published PRWeb - Jun 30 2014]
Momentum Indicators for Health Care Sector Equi... [Published BioPortfolio - Jun 13 2014]
Health Care Sector Equities Technical Analysis ... [Published Financial Services - May 14 2014]
CombiMatrix Announces LI Path Now Offering Comp... [Published GlobeNewswire: Advertising News - May 13 2014]
CombiMatrix Corporation to Release First Quarte... [Published GlobeNewswire: Acquisitions News - Apr 30 2014]
CombiMatrix Names Trilochan Sahoo, M.D., Direct... [Published GlobeNewswire: Acquisitions News - Apr 09 2014]
Technical Pointers - Top Gainers: Celldex Thera... [Published PR Newswire - Mar 18 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Press Releases

sort by: Date | Relevance
CombiMatrix Reports Second Quarter 2014 Financi... [Published GlobeNewswire: Acquisitions News - Aug 06 2014]
CombiMatrix Signs Contract With Stratose Networ... [Published GlobeNewswire: Advertising News - Jul 22 2014]
CombiMatrix's Pediatric Development Disorders A... [Published GlobeNewswire: Advertising News - Jul 15 2014]
Health Care Sector Equities Technical Analysis ... [Published Financial Services - May 14 2014]
CombiMatrix Announces LI Path Now Offering Comp... [Published GlobeNewswire: Advertising News - May 13 2014]
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.